비판막성심방세동 환자에서 직접작용 경구용 항응고제 임상적 효과와 부작용 연구
Clinical outcomes of direct-acting oral anticoagulants compared to warfarin in patients with non-valvular atrial fibrillation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Non-valvular atrial fibrillation (NVAF) is associated with ischemic stroke risk in the aging population. Observational studies have indicated beneficial effects of direct-acting oral anticoagulant (DOAC) against ischemic stroke compared to warfarin. This study aimed to investigate ischemic stroke incidence and bleeding risk in patients on DOAC therapy. Methods: Using the database of Korean Health Insurance Review and Assessment-Aged Patient Sample 2015, we conducted a retrospective cohort study. Study subjects with NVAF diagnosis and prescribed anticoagulants were enrolled. Propensity score (PS) matching by age, sex, comorbidities, and medications were used. The clinical outcomes were major adverse cerebro-cardiovascular events (MACCEs, ischemic stroke/systemic embolism, myocardial infarction, cardiac death) and bleeding events. A cox proportional hazard model analysis was performed to compare the outcomes with hazard ratio (HR) and 95% confidence interval (CI). Results: Total 4,773 elderly patients with NVAF were initially included. Four PS-matched groups including rivaroxaban vs. warfarin-only (n=1,079), dabigatran vs. warfarin-only (n=721), rivaroxaban vs. dabigatran (n=721), and switchers of warfarin to rivaroxaban vs. warfarinonly (n=287) were analyzed. Every group showed statistically similar results of MACCEs and bleeding events, except for the group of rivaroxaban vs. dabigatran. Rivaroxaban users showed higher risks of bleeding events than dabigatran users (HR 2.25, 95% CI 1.01-4.99). Conclusion: In the elderly patients with NVAF, efficacy and safety outcomes among oral anticoagulants including DOACs and warfarin were similar, while rivaroxaban are more likely to have higher bleeding risks than dabigatran. Further research using large size sample is needed.
Abstract
Background: Non-valvular atrial fibrillation (NVAF) is associated with ischemic stroke risk in the aging population. Observational studies have indicated beneficial effects of direct-acting oral anticoagulant (DOAC) against ischemic stroke compared to warfarin. This study aimed to investigate ischemic stroke incidence and bleeding risk in patients on DOAC therapy. Methods: Using the database of Korean Health Insurance Review and Assessment-Aged Patient Sample 2015, we conducted a retrospective cohort study. Study subjects with NVAF diagnosis and prescribed anticoagulants were enrolled. Propensity score (PS) matching by age, sex, comorbidities, and medications were used. The clinical outcomes were major adverse cerebro-cardiovascular events (MACCEs, ischemic stroke/systemic embolism, myocardial infarction, cardiac death) and bleeding events. A cox proportional hazard model analysis was performed to compare the outcomes with hazard ratio (HR) and 95% confidence interval (CI). Results: Total 4,773 elderly patients with NVAF were initially included. Four PS-matched groups including rivaroxaban vs. warfarin-only (n=1,079), dabigatran vs. warfarin-only (n=721), rivaroxaban vs. dabigatran (n=721), and switchers of warfarin to rivaroxaban vs. warfarinonly (n=287) were analyzed. Every group showed statistically similar results of MACCEs and bleeding events, except for the group of rivaroxaban vs. dabigatran. Rivaroxaban users showed higher risks of bleeding events than dabigatran users (HR 2.25, 95% CI 1.01-4.99). Conclusion: In the elderly patients with NVAF, efficacy and safety outcomes among oral anticoagulants including DOACs and warfarin were similar, while rivaroxaban are more likely to have higher bleeding risks than dabigatran. Further research using large size sample is needed.
참고문헌 (19)
- Norby FL, "Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation", BMC Cardiovasc Disord, 17(1), pp.238~ (2017)
- Bengtson LG, "Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation", J Cardiol, 69(6), pp.868~876 (2017)
- Escobar C, "A Delphi consensus on the management of oral anticoagulation in patients with nonvalvular atrial fibrillation in Spain : ACOPREFERENCE study", PloS one, 15(6), pp.e0231565~ (2020)
- Hill NR, "A systematic review of network meta-analyses and real-world evidence comparing apixaban and rivaroxaban in nonvalvular atrial fibrillation", Clin Appl Thromb Hemost, 26, pp.1076029619898764~ (2020)
- 고영진, "Impact of the Health Insurance Coverage Policy on Oral Anticoagulant Prescription among Patients with Atrial Fibrillation in Korea from 2014 to 2016", Journal of Korean Medical Science, 33(23), pp.1~12 (2018), 대한의학회
- Lee I, "Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea", J Cardiol, 66(6), pp.475~481 (2015)
- Han S, "The treatment pattern and adherence to direct oral anticoagulants in patients with atrial fibrillation aged over 65", PloS One, 14(4), pp.e0214666~ (2019)
- Chen A, "Direct oral anticoagulant use : a practical guide to common clinical challenges", J Am Heart Assoc, 9(13), pp.e017559~ (2020)
- January CT, "2019 AHA", ACC, ACC, pp.HRS guideline for the management of patients with atrial fibrillation : a report of the American College of Cardiology, American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[DOI]
- Manuel Anguita Sánchez, "Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study", Revista Española de Cardiología (English Edition), 73(1), pp.14~20 (2020), Elsevier BV[DOI]
- Anghel L, "Non-vitamin K antagonist oral anticoagulants and the gastrointestinal bleeding risk in real-world studies", J Clin Med, 9(5), pp.1398~ (2020)
- Lip GY, "Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients : the ARISTOPHANES study", Stroke, 49(12), pp.2933~2944 (2018)
- Rutherford OW, "Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study", Eur Heart J Cardiovasc Pharmacother, 6(2), pp.75~85 (2020)
- Patel MR, "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365(10), pp.883~891 (2011)
- Kim YH, "A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia", J Arrhythm, 34(4), pp.418~427 (2018)
- Camm AJ, "XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation", Eur Heart J, 37(14), pp.1145~1153 (2016)
- Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361(12), pp.1139~1151 (2009)
- Miller CS, "Metaanalysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation", Am J Cardiol, 110(3), pp.453~460 (2012)
- Peter AN, "Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation", Chest, 150(6), pp.1302~1312 (2016)